A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
The “2022 Refractive Surgery Market Report” analyzes the global refractive and presbyopia-correcting market, identifying important trends and key factors for future success. It focuses on the 2022 refractive and presbyopia-correcting surgical market and forecasts market growth and evolution over the next five years. Included are discussions and market estimates for LASIK, lenticular extraction, phakic IOLs, refractive lens exchange (RLE), and other technologies that may disrupt the market.
Sight Sciences reported March 13 that it generated 2022 total revenue of $71.3 million, an increase of 46 percent over $49.0 million in 2021. Surgical glaucoma revenue in 2022 was $65.6 million, an...
Shanghai-based AffaMed Technologies announced March 20 that the Taiwan Food and Drug Administration had approved the Mini Well, Mini Well Proxa, Mini Well Toric, and Mini 4 Ready intraocular lenses...
Investigators at Cedars-Sinai Medical Center in Los Angeles have analyzed changes in the retina and how they correspond to brain and cognitive changes in patients with Alzheimer’s disease. They say...
HCP Cureblindness, formerly known as the Himalayan Cataract Project, reported March 16 that it would immediately acquire the SightLife International Program, the global division of Seattle-based Si...
Sight Sciences announced March 9 that it had launched the Ergo-Series of its OMNI glaucoma surgical system in the US. It is expected to be available outside the US later this year, the company said...
Neurophth Therapeutics announced March 7 that a Maltese college student with ND1-associated Leber hereditary optic neuropathy (LHON) received treatment free of charge with the company’s investigati...
Cognition Therapeutics announced March 15 that the US FDA had cleared its investigational new drug (IND) application for a Phase II study of CT1812 for geographic atrophy (GA) secondary to dry age-...
Abeona Therapeutics, of New York and Cleveland, unveiled on March 14 three preclinical gene therapy product candidates from its ophthalmology program. Abeona says ABO-504 is designed to reconstitut...
On average, our surveys take only 5 to 15 minutes to complete. Survey results help you analyze practice patterns, evaluate treatment choices, and benchmark your practice.
Benchmark reports allow you to gauge your performance, track your practice metrics over time, and compare your practice to national averages.
Additional free data tools include instant survey results, weekly polls, PowerPoint charts, and more.
Learn More Register TodayA Multi-Step Approach for Accurate & Timely Data
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.